ID   MOT1_HUMAN              Reviewed;         500 AA.
AC   P53985; Q49A45; Q5T8R6; Q9NSJ9;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   30-NOV-2010, sequence version 3.
DT   10-MAY-2017, entry version 172.
DE   RecName: Full=Monocarboxylate transporter 1;
DE            Short=MCT 1;
DE   AltName: Full=Solute carrier family 16 member 1;
GN   Name=SLC16A1; Synonyms=MCT1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT GLU-490.
RC   TISSUE=Heart;
RX   PubMed=7835905; DOI=10.1006/geno.1994.1532;
RA   Garcia C.K., Li X., Luna J., Francke U.;
RT   "cDNA cloning of the human monocarboxylate transporter 1 and
RT   chromosomal localization of the SLC16A1 locus to 1p13.2-p12.";
RL   Genomics 23:500-503(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Colon;
RX   PubMed=11944921; DOI=10.1006/bbrc.2002.6763;
RA   Cuff M.A., Shirazi-Beechey S.P.;
RT   "The human monocarboxylate transporter, MCT1: genomic organization and
RT   promoter analysis.";
RL   Biochem. Biophys. Res. Commun. 292:1048-1056(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT
RP   GLU-490.
RC   TISSUE=Melanoma;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Brain, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=15505343; DOI=10.1369/jhc.4A6306.2004;
RA   Merezhinskaya N., Ogunwuyi S.A., Mullick F.G., Fishbein W.N.;
RT   "Presence and localization of three lactic acid transporters (MCT1,
RT   -2, and -4) in separated human granulocytes, lymphocytes, and
RT   monocytes.";
RL   J. Histochem. Cytochem. 52:1483-1493(2004).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-213 AND SER-498, VARIANT
RP   [LARGE SCALE ANALYSIS] GLU-490, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [9]
RP   INTERACTION WITH BSG, AND SUBCELLULAR LOCATION.
RX   PubMed=17127621; DOI=10.1080/09687860600841967;
RA   Manoharan C., Wilson M.C., Sessions R.B., Halestrap A.P.;
RT   "The role of charged residues in the transmembrane helices of
RT   monocarboxylate transporter 1 and its ancillary protein basigin in
RT   determining plasma membrane expression and catalytic activity.";
RL   Mol. Membr. Biol. 23:486-498(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-461 AND SER-498, VARIANT
RP   [LARGE SCALE ANALYSIS] GLU-490, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-461; SER-467; SER-483
RP   AND SER-498, VARIANT [LARGE SCALE ANALYSIS] GLU-490, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-461, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-213; SER-483 AND
RP   SER-498, VARIANT [LARGE SCALE ANALYSIS] GLU-490, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-213; THR-466; SER-483
RP   AND SER-498, VARIANT [LARGE SCALE ANALYSIS] GLU-490, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [16]
RP   REVIEW.
RX   PubMed=22162139; DOI=10.1002/iub.572;
RA   Halestrap A.P., Wilson M.C.;
RT   "The monocarboxylate transporter family--role and regulation.";
RL   IUBMB Life 64:109-119(2012).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-461; THR-466; SER-467;
RP   SER-483 AND SER-498, VARIANT [LARGE SCALE ANALYSIS] GLU-490, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-467 AND SER-498, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [19]
RP   INVOLVEMENT IN MCT1D, AND VARIANT MCT1D GLN-313.
RX   PubMed=25390740; DOI=10.1056/NEJMoa1407778;
RA   van Hasselt P.M., Ferdinandusse S., Monroe G.R., Ruiter J.P.,
RA   Turkenburg M., Geerlings M.J., Duran K., Harakalova M.,
RA   van der Zwaag B., Monavari A.A., Okur I., Sharrard M.J., Cleary M.,
RA   O'Connell N., Walker V., Rubio-Gozalbo M.E., de Vries M.C., Visser G.,
RA   Houwen R.H., van der Smagt J.J., Verhoeven-Duif N.M., Wanders R.J.,
RA   van Haaften G.;
RT   "Monocarboxylate transporter 1 deficiency and ketone utilization.";
RL   N. Engl. J. Med. 371:1900-1907(2014).
RN   [20]
RP   SUBCELLULAR LOCATION.
RX   PubMed=24390345; DOI=10.1038/nature12828;
RG   The SIGMA Type 2 Diabetes Consortium;
RT   "Sequence variants in SLC16A11 are a common risk factor for type 2
RT   diabetes in Mexico.";
RL   Nature 506:97-101(2014).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   VARIANTS SDLT GLU-204 AND ARG-472, AND VARIANT GLU-490.
RX   PubMed=10590411;
RX   DOI=10.1002/(SICI)1097-4598(200001)23:1<90::AID-MUS12>3.0.CO;2-M;
RA   Merezhinskaya N., Fishbein W.N., Davis J.I., Foellmer J.W.;
RT   "Mutations in MCT1 cDNA in patients with symptomatic deficiency in
RT   lactate transport.";
RL   Muscle Nerve 23:90-97(2000).
RN   [23]
RP   INVOLVEMENT IN HHF7, AND FUNCTION.
RX   PubMed=17701893; DOI=10.1086/520960;
RA   Otonkoski T., Jiao H., Kaminen-Ahola N., Tapia-Paez I., Ullah M.S.,
RA   Parton L.E., Schuit F., Quintens R., Sipilae I., Mayatepek E.,
RA   Meissner T., Halestrap A.P., Rutter G.A., Kere J.;
RT   "Physical exercise-induced hypoglycemia caused by failed silencing of
RT   monocarboxylate transporter 1 in pancreatic beta cells.";
RL   Am. J. Hum. Genet. 81:467-474(2007).
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] GLU-490, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
CC   -!- FUNCTION: Proton-coupled monocarboxylate transporter. Catalyzes
CC       the rapid transport across the plasma membrane of many
CC       monocarboxylates such as lactate, pyruvate, branched-chain oxo
CC       acids derived from leucine, valine and isoleucine, and the ketone
CC       bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending
CC       on the tissue and on cicumstances, mediates the import or export
CC       of lactic acid and ketone bodies. Required for normal nutrient
CC       assimilation, increase of white adipose tissue and body weight
CC       gain when on a high-fat diet. Plays a role in cellular responses
CC       to a high-fat diet by modulating the cellular levels of lactate
CC       and pyruvate, small molecules that contribute to the regulation of
CC       central metabolic pathways and insulin secretion, with concomitant
CC       effects on plasma insulin levels and blood glucose homeostasis.
CC       {ECO:0000269|PubMed:17701893}.
CC   -!- SUBUNIT: Interacts with EMB. Interaction with either BSG or EMB is
CC       required for expression at the cell membrane (By similarity).
CC       Interacts with BSG; this is required for expression at the cell
CC       membrane. {ECO:0000250, ECO:0000269|PubMed:17127621}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15505343,
CC       ECO:0000269|PubMed:17127621, ECO:0000269|PubMed:24390345}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:15505343,
CC       ECO:0000269|PubMed:17127621, ECO:0000269|PubMed:24390345}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P53985-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P53985-2; Sequence=VSP_056191;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in heart and in blood lymphocytes and
CC       monocytes (at protein level). Widely expressed.
CC       {ECO:0000269|PubMed:15505343}.
CC   -!- DISEASE: Symptomatic deficiency in lactate transport (SDLT)
CC       [MIM:245340]: Deficiency of lactate transporter may result in an
CC       acidic intracellular environment created by muscle activity with
CC       consequent degeneration of muscle and release of myoglobin and
CC       creatine kinase. This defect might compromise extreme performance
CC       in otherwise healthy individuals. {ECO:0000269|PubMed:10590411}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Familial hyperinsulinemic hypoglycemia 7 (HHF7)
CC       [MIM:610021]: Dominantly inherited hypoglycemic disorder
CC       characterized by inappropriate insulin secretion during anaerobic
CC       exercise or on pyruvate load. {ECO:0000269|PubMed:17701893}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Monocarboxylate transporter 1 deficiency (MCT1D)
CC       [MIM:616095]: A metabolic disorder characterized by recurrent
CC       ketoacidosis, a pathologic state due to ketone formation exceeding
CC       ketone utilization. The clinical consequences of ketoacidosis are
CC       vomiting, osmotic diuresis, dehydration, and Kussmaul breathing.
CC       The condition may progress to decreased consciousness and,
CC       ultimately, death. {ECO:0000269|PubMed:25390740}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- MISCELLANEOUS: Overexpression in pancreatic beta-cells triggers
CC       insulin secretion in response to pyruvate, causing hyperinsulemia
CC       and hypoglycemia during strenuous exercise.
CC   -!- SIMILARITY: Belongs to the major facilitator superfamily.
CC       Monocarboxylate porter (TC 2.A.1.13) family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/SLC16A1ID44046ch1p13.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L31801; AAC41707.1; -; mRNA.
DR   EMBL; AJ438945; CAD27707.1; -; Genomic_DNA.
DR   EMBL; AL162079; CAB82412.1; -; mRNA.
DR   EMBL; AL158844; CAI21872.1; -; Genomic_DNA.
DR   EMBL; CH471122; EAW56552.1; -; Genomic_DNA.
DR   EMBL; BC026317; AAH26317.1; -; mRNA.
DR   EMBL; BC045664; AAH45664.1; -; mRNA.
DR   CCDS; CCDS858.1; -. [P53985-1]
DR   PIR; A55568; A55568.
DR   RefSeq; NP_001159968.1; NM_001166496.1. [P53985-1]
DR   RefSeq; NP_003042.3; NM_003051.3. [P53985-1]
DR   RefSeq; XP_011540328.1; XM_011542026.2. [P53985-1]
DR   RefSeq; XP_011540329.1; XM_011542027.2. [P53985-1]
DR   UniGene; Hs.75231; -.
DR   ProteinModelPortal; P53985; -.
DR   BioGrid; 112454; 24.
DR   IntAct; P53985; 12.
DR   MINT; MINT-5004345; -.
DR   STRING; 9606.ENSP00000358640; -.
DR   BindingDB; P53985; -.
DR   ChEMBL; CHEMBL4360; -.
DR   DrugBank; DB04319; 6-Deoxyglucose.
DR   DrugBank; DB03166; Acetic acid.
DR   DrugBank; DB01762; Acetoacetic Acid.
DR   DrugBank; DB04074; Alpha-ketoisovalerate.
DR   DrugBank; DB00345; Aminohippuric acid.
DR   DrugBank; DB00415; Ampicillin.
DR   DrugBank; DB08892; Arbaclofen Placarbil.
DR   DrugBank; DB03793; Benzoic Acid.
DR   DrugBank; DB03066; D-Lactic Acid.
DR   DrugBank; DB00529; Foscarnet.
DR   DrugBank; DB01440; Gamma Hydroxybutyric Acid.
DR   DrugBank; DB00142; L-Glutamic Acid.
DR   DrugBank; DB04398; Lactic Acid.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB00731; Nateglinide.
DR   DrugBank; DB00627; Niacin.
DR   DrugBank; DB04552; Niflumic Acid.
DR   DrugBank; DB00175; Pravastatin.
DR   DrugBank; DB01032; Probenecid.
DR   DrugBank; DB00119; Pyruvic acid.
DR   DrugBank; DB04216; Quercetin.
DR   DrugBank; DB00936; Salicylic acid.
DR   DrugBank; DB04348; Taurocholic Acid.
DR   DrugBank; DB00313; Valproic Acid.
DR   GuidetoPHARMACOLOGY; 988; -.
DR   TCDB; 2.A.1.13.1; the major facilitator superfamily (mfs).
DR   iPTMnet; P53985; -.
DR   PhosphoSitePlus; P53985; -.
DR   SwissPalm; P53985; -.
DR   BioMuta; SLC16A1; -.
DR   DMDM; 313104214; -.
DR   EPD; P53985; -.
DR   MaxQB; P53985; -.
DR   PaxDb; P53985; -.
DR   PeptideAtlas; P53985; -.
DR   PRIDE; P53985; -.
DR   DNASU; 6566; -.
DR   Ensembl; ENST00000369626; ENSP00000358640; ENSG00000155380. [P53985-1]
DR   Ensembl; ENST00000538576; ENSP00000441065; ENSG00000155380. [P53985-1]
DR   Ensembl; ENST00000628110; ENSP00000485688; ENSG00000281917. [P53985-1]
DR   Ensembl; ENST00000630362; ENSP00000486000; ENSG00000281917. [P53985-1]
DR   GeneID; 6566; -.
DR   KEGG; hsa:6566; -.
DR   UCSC; uc001ecx.4; human. [P53985-1]
DR   CTD; 6566; -.
DR   DisGeNET; 6566; -.
DR   GeneCards; SLC16A1; -.
DR   H-InvDB; HIX0000897; -.
DR   HGNC; HGNC:10922; SLC16A1.
DR   HPA; CAB017489; -.
DR   HPA; HPA003324; -.
DR   HPA; HPA071055; -.
DR   MalaCards; SLC16A1; -.
DR   MIM; 245340; phenotype.
DR   MIM; 600682; gene.
DR   MIM; 610021; phenotype.
DR   MIM; 616095; phenotype.
DR   neXtProt; NX_P53985; -.
DR   OpenTargets; ENSG00000155380; -.
DR   Orphanet; 165991; Exercise-induced hyperinsulinism.
DR   Orphanet; 171690; Metabolic myopathy due to lactate transporter defect.
DR   PharmGKB; PA35813; -.
DR   eggNOG; KOG2504; Eukaryota.
DR   eggNOG; COG0477; LUCA.
DR   GeneTree; ENSGT00760000118926; -.
DR   HOGENOM; HOG000280688; -.
DR   HOVERGEN; HBG006384; -.
DR   InParanoid; P53985; -.
DR   KO; K08179; -.
DR   OMA; HMLAPLS; -.
DR   OrthoDB; EOG091G05SW; -.
DR   PhylomeDB; P53985; -.
DR   TreeFam; TF313792; -.
DR   BioCyc; MetaCyc:ENSG00000155380-MONOMER; -.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-433692; Proton-coupled monocarboxylate transport.
DR   Reactome; R-HSA-70268; Pyruvate metabolism.
DR   SABIO-RK; P53985; -.
DR   ChiTaRS; SLC16A1; human.
DR   GenomeRNAi; 6566; -.
DR   PMAP-CutDB; P53985; -.
DR   PRO; PR:P53985; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000155380; -.
DR   CleanEx; HS_SLC16A1; -.
DR   ExpressionAtlas; P53985; baseline and differential.
DR   Genevisible; P53985; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005813; C:centrosome; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0015129; F:lactate transmembrane transporter activity; EXP:Reactome.
DR   GO; GO:0015130; F:mevalonate transmembrane transporter activity; TAS:ProtInc.
DR   GO; GO:0008028; F:monocarboxylic acid transmembrane transporter activity; TAS:Reactome.
DR   GO; GO:0097159; F:organic cyclic compound binding; IEA:Ensembl.
DR   GO; GO:0042803; F:protein homodimerization activity; IEA:Ensembl.
DR   GO; GO:0015293; F:symporter activity; IEA:UniProtKB-KW.
DR   GO; GO:0051780; P:behavioral response to nutrient; IEA:Ensembl.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IEA:Ensembl.
DR   GO; GO:0051297; P:centrosome organization; IMP:UniProtKB.
DR   GO; GO:0042593; P:glucose homeostasis; IEA:Ensembl.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:Ensembl.
DR   GO; GO:0015728; P:mevalonate transport; TAS:ProtInc.
DR   GO; GO:0015718; P:monocarboxylic acid transport; TAS:ProtInc.
DR   GO; GO:0035879; P:plasma membrane lactate transport; ISS:UniProtKB.
DR   GO; GO:0006090; P:pyruvate metabolic process; TAS:Reactome.
DR   GO; GO:0050796; P:regulation of insulin secretion; IEA:Ensembl.
DR   GO; GO:0032094; P:response to food; IEA:Ensembl.
DR   CDD; cd06174; MFS; 1.
DR   InterPro; IPR004743; MCT.
DR   InterPro; IPR030757; MCT1.
DR   InterPro; IPR011701; MFS.
DR   InterPro; IPR020846; MFS_dom.
DR   PANTHER; PTHR11360:SF170; PTHR11360:SF170; 1.
DR   Pfam; PF07690; MFS_1; 1.
DR   SUPFAM; SSF103473; SSF103473; 2.
DR   TIGRFAMs; TIGR00892; 2A0113; 1.
DR   PROSITE; PS50850; MFS; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Symport; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN         1    500       Monocarboxylate transporter 1.
FT                                /FTId=PRO_0000211381.
FT   TOPO_DOM      1     15       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     16     36       Helical. {ECO:0000255}.
FT   TOPO_DOM     37     59       Extracellular. {ECO:0000255}.
FT   TRANSMEM     60     80       Helical. {ECO:0000255}.
FT   TOPO_DOM     81     86       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     87    107       Helical. {ECO:0000255}.
FT   TOPO_DOM    108    111       Extracellular. {ECO:0000255}.
FT   TRANSMEM    112    132       Helical. {ECO:0000255}.
FT   TOPO_DOM    133    143       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    144    164       Helical. {ECO:0000255}.
FT   TOPO_DOM    165    166       Extracellular. {ECO:0000255}.
FT   TRANSMEM    167    187       Helical. {ECO:0000255}.
FT   TOPO_DOM    188    262       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    263    283       Helical. {ECO:0000255}.
FT   TOPO_DOM    284    298       Extracellular. {ECO:0000255}.
FT   TRANSMEM    299    319       Helical. {ECO:0000255}.
FT   TOPO_DOM    320    328       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    329    349       Helical. {ECO:0000255}.
FT   TOPO_DOM    350    353       Extracellular. {ECO:0000255}.
FT   TRANSMEM    354    374       Helical. {ECO:0000255}.
FT   TOPO_DOM    375    389       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    390    410       Helical. {ECO:0000255}.
FT   TOPO_DOM    411    422       Extracellular. {ECO:0000255}.
FT   TRANSMEM    423    443       Helical. {ECO:0000255}.
FT   TOPO_DOM    444    500       Cytoplasmic. {ECO:0000255}.
FT   MOD_RES     210    210       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P53986}.
FT   MOD_RES     213    213       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692}.
FT   MOD_RES     231    231       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P53986}.
FT   MOD_RES     461    461       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19369195,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     466    466       Phosphothreonine.
FT                                {ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     467    467       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     483    483       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     498    498       Phosphoserine.
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   VAR_SEQ     411    500       RLNDMYGDYKYTYWACGVVLIISGIYLFIGMGINYRLLAKE
FT                                QKANEQKKESKEEETSIDVAGKPNEVTKAAESPDQKDTDGG
FT                                PKEEESPV -> IVYLPTNVGLLQNKHVRWEC (in
FT                                isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_056191.
FT   VARIANT      85     85       S -> G (in dbSNP:rs11551867).
FT                                /FTId=VAR_054804.
FT   VARIANT     204    204       K -> E (in SDLT; dbSNP:rs80358222).
FT                                {ECO:0000269|PubMed:10590411}.
FT                                /FTId=VAR_010434.
FT   VARIANT     313    313       R -> Q (in MCT1D; dbSNP:rs606231302).
FT                                {ECO:0000269|PubMed:25390740}.
FT                                /FTId=VAR_072428.
FT   VARIANT     472    472       G -> R (in SDLT; dbSNP:rs72552271).
FT                                {ECO:0000269|PubMed:10590411}.
FT                                /FTId=VAR_010435.
FT   VARIANT     490    490       D -> E (in dbSNP:rs1049434).
FT                                {ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21269460,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:10590411,
FT                                ECO:0000269|PubMed:17974005,
FT                                ECO:0000269|PubMed:7835905}.
FT                                /FTId=VAR_010436.
FT   CONFLICT    480    480       A -> T (in Ref. 1; AAC41707).
FT                                {ECO:0000305}.
SQ   SEQUENCE   500 AA;  53944 MW;  3F5B048CB962ECC8 CRC64;
     MPPAVGGPVG YTPPDGGWGW AVVIGAFISI GFSYAFPKSI TVFFKEIEGI FHATTSEVSW
     ISSIMLAVMY GGGPISSILV NKYGSRIVMI VGGCLSGCGL IAASFCNTVQ QLYVCIGVIG
     GLGLAFNLNP ALTMIGKYFY KRRPLANGLA MAGSPVFLCT LAPLNQVFFG IFGWRGSFLI
     LGGLLLNCCV AGALMRPIGP KPTKAGKDKS KASLEKAGKS GVKKDLHDAN TDLIGRHPKQ
     EKRSVFQTIN QFLDLTLFTH RGFLLYLSGN VIMFFGLFAP LVFLSSYGKS QHYSSEKSAF
     LLSILAFVDM VARPSMGLVA NTKPIRPRIQ YFFAASVVAN GVCHMLAPLS TTYVGFCVYA
     GFFGFAFGWL SSVLFETLMD LVGPQRFSSA VGLVTIVECC PVLLGPPLLG RLNDMYGDYK
     YTYWACGVVL IISGIYLFIG MGINYRLLAK EQKANEQKKE SKEEETSIDV AGKPNEVTKA
     AESPDQKDTD GGPKEEESPV
//
